References
- http://www.alsuntangled.com/open.php. Accessed December 2, 2015.
- Geffard M, Bisschop L, Duleu S, Pouns O, Ferran G, Bessede A, et al. Endotherapia. Anti-inflammatory and Anti-aging Agents in Medicinal Chemistry. 2010;9:197–211.
- Geffard M, Duleu S, Bessede A, Vigier V, Bodet D, Mangas A, et al. GEMSP: A New Therapeutic Approach to Multiple Sclerosis. Central Nervous System Agents in Medicinal Chemistry. 2012;12:1730–81.
- Geffard M, DeBisschop L, Duleu S, Hassaine N, Mangas A, Covenas R. Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases. Discovery Medicine. 2010;10:443–51.
- http://www.idrpht.info/Immuno-Bilan#/Immuno-Bilan/. Accessed December 3, 2015.
- Email between ALSUntangled and Dr. M Geffard, November 6, 2015.
- Telephone conversation between ALSUntangled and ‘Pierre’, a researcher working with Dr. M Geffard, November 9, 2015.
- Leinweber B, Barofsy E, Barofsky D, Emilov V, Nylin K, Beckman J. Aggregation of ALS mutant superoxide dismutase expressed in Escherichia coli. Free Radical Biology and Medicine. 2004;36:911–8.
- Bradley W, Mash D. Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph Lateral Scler. 2009;S2:7–20.
- Chen S, Sayana P, Zhang X, Le W. Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener. 2013;9:28.
- Kaufmann P, Thompson J, Buchsbaum R, Shefner J, Krivickas L, Katz J, et al. Phase II trial of coq10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:234–44.
- Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm. 2005;112:646–60.
- Duleu S, van der Velden C, Poulletier de Gannes F, Tranchant M, Geffard M. Circulating antibodies to NO- and ONOO-modified antigens in amyotrophic lateral sclerosis, Alzheimer’s disease and multiple sclerosis. Immuno-anlayse et biologie specialisee. 2007:22:273–81.
- Duleu S, Mangas A, Poulletier de Gannes F, Tranchant M, Geffard M. Circulating antibodies to conjugated tryptophan derivatives of the IDO pathway in amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s and multiple sclerosis patients. Immuno-anlayse et biologie specialisee. 2008:23:27–34.
- Duleu S, Sevin F, Bessede A, Ferrand G, Poullettier De Gannes F, et al. The indirect involvement of radical processes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;S1:158.
- Nicase C, Coupier J, Dabadie M, de Decker R, Mangas A, Boudet D, et al. Gemals, a new drug candidate, extends lifespan and improves electromyographic parameters in a rat model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:85–90.
- Ludolph A, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11:38–45.
- http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6114388.PN.&OS=PN/6114388&RS=PN/6114388. Accessed November 27, 2015.
- https://www.patientslikeme.com/search?utf8=✓&cx=016260609975327438954%3Amf0ormpzdl4&ie=UTF-8&q=endotherapia. Accessed November 27, 2015.
- http://www.illawarramercury.com.au/story/3219048/new-treatment-hope-for-bulli-mnd-sufferer/. Accessed November 27, 2015.
- http://www.alstdi.org/forum/yaf_postst54957p3_endotherapia-treatment-for-mnd-real-progress-or-placebo.aspx. Accessed November 29, 2015.
- https://www.inspire.com/groups/als-association/discussion/endotherapia/. Accessed December 2, 2015.
- http://forum.mndassociation.org/showthread.php?6540-Endotherapia. Accessed December 2, 2015.
- Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neuron disease: the ALSAQ40. J Neurol. 1999;246s3:16–21.
- Lule D, Hacker S, Ludolph A, Birbaumer N, Kubler A. Depression and quality of life in patients with amyotrophic lateral sclerosis. Dtsch Arztebl Int. 2008;105:397–403.
- van Groenestijn A, Schroeder C, Visser-Meuly V, Reenen ET, Veldink J, van Den Berg L. Cognitive behavioural therapy and quality of life in psychologically distressed patients with amyotrophic lateral sclerosis and their caregivers: results of a prematurely stopped randomized controlled trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:309–15.
- Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10:661–70.
- Donofrio P, Bedlack R. Historical controls in ALS trials: a high seas rescue? Neurology. 2011;6:936–7.
- Benatar M. Lost in translation: treatment trials in the SOD1 mouse and human ALS. Neurobiol Dis. 2007;26:1–13.